Clinical trials
Colitis clinical trials
Below are recruiting colitis clinical trials, each written for real people, not researchers. We’re tracking 321 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Phoenix, ArizonaAges 2–17 - NCT05218850RecruitingPhase 2
Butyrate treatment for kids with mild-to-moderate ulcerative colitis
This trial tests whether butyrate can help children and teens with mild-to-moderate ulcerative colitis (a long-term bowel inflammation condition). You may be able to join if your symptoms fit the study level and you haven’t recently started other specific ulcerative colitis treatments right before the study begins.
Los Angeles, CaliforniaAges 7–21 - NCT05327790RecruitingPhase 2
Fecal transplant to boost new biologic treatment for ulcerative colitis
This trial tests whether fecal microbiota transfer (a stool-based therapy) can improve outcomes when added to starting a new biologic medicine for ulcerative colitis. It compares fecal transplant versus placebo (a sham treatment) to see if symptoms and inflammation improve faster or more strongly.
Edmonton, AlbertaAges 18–75 - NCT05333471RecruitingPhase 1/Phase 2
Fecal transplant for chronic bowel inflammation in CGD
This study tests whether transplanting stool microbiome (fecal microbiota transplant) can improve chronic colitis in people with chronic granulomatous disease (CGD). It aims to reduce bowel inflammation and symptoms by changing gut bacteria.
Bethesda, MarylandAges 10–60 - NCT05428345Recruiting
Shot of vedolizumab skin injection for active bowel inflammation
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Mobile, AlabamaAges 2 years+ - NCT05456412Recruiting
JAK medicine for active ulcerative colitis
This study tests whether a JAK-inhibitor medicine can improve symptoms in people with active ulcerative colitis. If you’re currently flaring, it may help calm inflammation and reduce symptoms.
Leiden, South HollandAges 16–65 - NCT05456893Recruiting
Testing blood and stool markers in active ulcerative colitis treatments
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
Nancy, LorraineAges 18 years+ - NCT05479617Recruiting
Predicting ulcerative colitis flare course using personal data
This study tries to better predict how an ulcerative colitis flare will progress by using a mix of your medical information. If you are eligible, your flare details may help researchers build tools that guide future care.
Hvidovre, DenmarkAges 18 years+ - NCT05481619RecruitingPhase 4
Vedolizumab study for ulcerative colitis and gut changes
This trial tests whether vedolizumab helps people with moderate-to-severe ulcerative colitis and what changes happen in the gut microbiome (the community of helpful bacteria in your intestines). You may be able to join if you’re an adult with ulcerative colitis who has not used vedolizumab before and haven’t taken certain gut-affecting medicines recently.
Zhengzhou, HangzhouAges 18 years+ - NCT05610956RecruitingEarly Phase 1
Empagliflozin for mild-to-moderate ulcerative colitis
This early trial studies whether empagliflozin can improve ulcerative colitis symptoms and is safe for people with mild to moderate disease. If it works, it may reduce ongoing colon inflammation and help people feel better.
TantaAges 18–70 - NCT05698745Recruiting
Study of the immune features soon after bowel disease starts
This study looks at immune system changes in people around the time inflammatory bowel disease (IBD) is first diagnosed, and compares different groups (new, very recent, or not found on scope). It may help researchers understand what the immune system looks like early in IBD and later in people who don’t show it on colonoscopy.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT05704413Recruiting
Biobank study using gut tissue in bowel disease
This study collects and stores digestive (bowel) tissue to better understand how gut bacteria may affect diseases like ulcerative colitis or Crohn’s disease. It may help researchers find future ways to improve care for people with these conditions.
ParisAges 18 years+ - NCT05739864RecruitingPhase 1/Phase 2
Test of donor gut bacteria for ulcerative colitis
This early-stage study tests whether a one-time transfer of “donor gut bacteria” can improve ulcerative colitis. It’s designed for people with mild to moderate ulcerative colitis who are stable on maintenance treatment.
Rome, LazioAges 18–75 - NCT05895981Recruiting
Sacral nerve stimulation for ulcerative colitis symptoms
This trial tests whether sacral nerve stimulation—a device that sends small electrical signals near nerves in the lower back—can be safe and helpful for ulcerative colitis. It is meant for people whose ulcerative colitis has not improved enough with medicines.
Xi'an, ShaanxiAges 18 years+ - NCT05947669RecruitingPhase 3
Infliximab for diarrhea or colitis from immune cancer therapy
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
AalborgAges 18 years+ - NCT05953402Recruiting
Testing ozanimod use in pregnant people with ulcerative colitis
This trial studies how ozanimod affects pregnant people with ulcerative colitis and their babies. It may help doctors understand safety and outcomes when this medicine is used during pregnancy and after birth.
Wilmington, North CarolinaAges Any age - NCT05987852Recruiting
Hyperbaric oxygen therapy for ulcerative colitis flare
This trial tests if hyperbaric oxygen therapy (breathing pure oxygen in a special chamber) can help people hospitalized with a moderate to severe ulcerative colitis flare get better faster. You will receive the therapy along with standard steroid treatment.
Birmingham, AlabamaAges 18–85 - NCT06029972RecruitingPhase 2
Experimental drug for moderate to severe ulcerative colitis
This trial tests an experimental medication (tilpisertib fosmecarbil) for people with moderate to severe ulcerative colitis who have already tried at least one advanced therapy but it didn't work well enough. The study aims to see if this new drug can help reduce inflammation and improve symptoms.
Sun City, ArizonaAges 18–75 - NCT06071312RecruitingPhase 1/Phase 2
Fecal transplant for C. diff and ulcerative colitis
This trial tests whether one or multiple fecal transplants from a healthy donor can help treat both a recurring C. diff infection and active ulcerative colitis. It aims to find the best schedule for the procedure.
RomeAges 18–75 - NCT06095596Recruiting
Combining vedolizumab and upadacitinib for ulcerative colitis
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
Guangzhou, GuangdongAges 18 years+ - NCT06206707Recruiting
FMT for Diarrhea and Colitis After Immunotherapy
This trial tests whether a treatment called fecal microbiota transplant (FMT) — transferring healthy gut bacteria — can help relieve diarrhea and colitis caused by immunotherapy drugs. If you have melanoma or kidney cancer and are experiencing diarrhea after immunotherapy, this study may offer a new option.
Aarhus NAges 18 years+ - NCT06213857RecruitingPhase 2
Silymarin for ulcerative colitis
This study tests whether silymarin (an extract from milk thistle) can help treat ulcerative colitis when added to your usual treatment. It may reduce inflammation and oxidative stress in the colon.
AsyutAges 18–65 - NCT06228352Recruiting
Bile acids and gut bacteria in C. difficile with ulcerative colitis
This study looks at how bile acids and gut bacteria relate to C. difficile infection in children with ulcerative colitis. It aims to find better ways to predict and treat these infections.
ParisAges Up to 17 years
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colitis?
- Yes. Clin2 currently lists 321 recruiting colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.